Active, not recruitingEarly Phase 1NCT05182905

AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients

Studying Giant cell glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Nader Sanai
Principal Investigator
Nader Sanai, MD, MD
Chief Scientific Officer/Director
Intervention
AZD1390(drug)
Enrollment
97 enrolled
Eligibility
18 years · All sexes
Timeline
20222026

Study locations (1)

Collaborators

Barrow Neurological Institute · Ivy Brain Tumor Center · AstraZeneca

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05182905 on ClinicalTrials.gov

Other trials for Giant cell glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Giant cell glioblastoma

← Back to all trials